Literature DB >> 30689515

Genetically detoxified pertussis toxin induces superior antigen specific CD4 T cell responses compared to chemically detoxified pertussis toxin.

Naveen Surendran1, Michael Pichichero1.   

Abstract

Pertussis is resurgent worldwide. Currently available acellular pertussis vaccines contain chemically detoxified pertussis toxin (PTc); a highly immunogenic genetically detoxified pertussis toxin (PTg) vaccine has been off the market for over a decade. We compared CD4+ T cell and B cell responses induced by genetically detoxified pertussis toxin (PTg) and chemically detoxified pertussis toxin (PTc) using naive human neonatal cells. Responses to novel adjuvants were also assessed. PTg induced significant antigen-specific CD4+ T cell activation and IL17 secretion than PTc. TLR agonist combinations improved PTg induced T cell-CD69 expression and IL17 secretion.

Entities:  

Keywords:  Pertussis; activation-induced marker assay; genetically detoxified pertussis toxin; neonatal T cell response; pediatric vaccines

Mesh：

Substances：

Year:  2019        PMID： 30689515      PMCID： PMC6605848          DOI： 10.1080/21645515.2019.1565270

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  16 in total

1.  Immunogenicity of a three-component acellular pertussis vaccine administered at birth.

Authors:  Cesare Belloni; Annalisa De Silvestri; Carmine Tinelli; Maria A Avanzini; Massimo Marconi; Fabio Strano; Giorgio Rondini; Gaetano Chirico
Journal:  Pediatrics       Date:  2003-05       Impact factor: 7.124

2.  A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Authors:  M E Pichichero; M A Deloria; M B Rennels; E L Anderson; K M Edwards; M D Decker; J A Englund; M C Steinhoff; A Deforest; B D Meade
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

3.  The pertussis problem.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2013-12-20       Impact factor: 9.079

4.  Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.

Authors:  M E Pichichero; K M Edwards; E L Anderson; M B Rennels; J A Englund; D E Yerg; W C Blackwelder; D L Jansen; B D Meade
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

5.  Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.

Authors:  Alicja Misiak; Rosanna Leuzzi; Aideen C Allen; Bruno Galletti; Barbara C Baudner; Ugo D'Oro; Derek T O'Hagan; Mariagrazia Pizza; Anja Seubert; Kingston H G Mills
Journal:  Vaccine       Date:  2017-08-18       Impact factor: 3.641

6.  Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.

Authors:  Michael E Pichichero; Margaret B Rennels; Kathryn M Edwards; Mark M Blatter; Gary S Marshall; Monica Bologa; Elaine Wang; Elaine Mills
Journal:  JAMA       Date:  2005-06-02       Impact factor: 56.272

7.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

8.  Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age.

Authors:  Nicholas Wood; Peter McIntyre; Helen Marshall; Don Roberton
Journal:  Pediatr Infect Dis J       Date:  2010-03       Impact factor: 2.129

9.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.

Authors:  Jason M Warfel; Lindsey I Zimmerman; Tod J Merkel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

10.  TLR agonist combinations that stimulate Th type I polarizing responses from human neonates.

Authors:  Naveen Surendran; Andrea Simmons; Michael E Pichichero
Journal:  Innate Immun       Date:  2018-04-19       Impact factor: 2.680
View more
  4 in total

Review 1.  Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.

Authors:  Kevin Markey; Catpagavalli Asokanathan; Ian Feavers
Journal:  Toxins (Basel)       Date:  2019-07-17       Impact factor: 4.546

2.  Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice.

Authors:  M Allison Wolf; Dylan T Boehm; Megan A DeJong; Ting Y Wong; Emel Sen-Kilic; Jesse M Hall; Catherine B Blackwood; Kelly L Weaver; Claire O Kelly; Caleb A Kisamore; Graham J Bitzer; Justin R Bevere; Mariette Barbier; F Heath Damron
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

3.  Evaluation of Outer Membrane Vesicles Obtained from Predominant Local Isolate of Boredetella pertussis as a Vaccine Candidate.

Authors:  Maryam Sadat Soltani; Mojtaba Noofeli; Seyed Reza Banihashemi; Fereshteh Shahcheraghi; Fereshteh Eftekhar
Journal:  Iran Biomed J       Date:  2021-11-01

Review 4.  Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality.

Authors:  Alex-Mikael Barkoff; Aapo Knuutila; Jussi Mertsola; Qiushui He
Journal:  Toxins (Basel)       Date:  2021-07-21       Impact factor: 4.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.